Aprotinin Injection (marketed as Trasylol)

November 7, 2007 by RecallAware
Filed under: Uncategorized 

Patient enrollment in the Aprotinin treatment group arm of BART study stopped due to preliminary findings that suggest an increased risk of death associated with aprotinin compared to other antifibrinolytic drugs.

Tags:

Comments

Readers of this site appreciate your comments

You must be logged in to post a comment.

References and links to other sites are provided as a courtesy. The recall and safety information provided here is based entirely on manufacturers' and regulatory agencies' press release or other public information. We make no other representations about the accuracy or timeliness of this information